Haemonetics (HAE) Tops Q3 EPS by 3c; Offers Guidance

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.85, $0.03 better than the analyst estimate of $0.82. Revenue for the quarter came in at $305.3 million versus the consensus estimate of $299.08 million.

GUIDANCE:

Haemonetics sees FY2023 EPS of $2.90-$3.00, versus the consensus of $2.92.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Citi upgrades Haemonetics to Buy, raises price target to $123
• Barclays says AI trade is maturing, favors greater diversification
• Nucor projects Q3 2026 earnings above prior year, below estimates